Almirall S.A. a global biopharmaceutical company dedicated to medical dermatology, has announced that NICE has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.
This GLP-1R / CRE Luciferase Reporter HEK293 cell line has been engineered to monitor activation of GLP-1R in cells by measuring luciferase activity, making it useful for cell-based binding assays and screening for human GLP-1R agonists.
Takeda have announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO (vedolizumab) subcutaneous administration for maintenance therapy in adults with moderately to severely active Crohn’s disease.
The UK MHRA has approved the combined antibiotic cefepime/enmetazobactam (Exblifep 2 g/0.5 g powder for concentrate for solution for infusion) to treat adult patients with complicated infections of the urinary tract.
The EMPACT-MI phase III clinical trial showed a 10% relative risk reduction in the primary composite endpoint of time to first hospitalisation due to heart failure or all-cause mortality for empagliflozin versus placebo.
MSD have announced that the U.S. FDA has approved sotatercept-csrk (U.S. Brand Name: WINREVAIR, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension.
Otsuka Pharmaceutical Europe and H. Lundbeck A/S have announced that the European Commission has approved Abilify Maintena 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the treatment of schizophrenia.
Corteria Pharmaceuticals have announced the initiation of its Phase 1 study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure.
Novo Nordisk have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended marketing authorisation for Awiqli for treatment of diabetes in adults.
Madrigal Pharmaceuticals have announced that the U.S. FDA has granted accelerated approval for Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH.
On Rare Disease Day 2024, we hear from Chris Moore, President, Veeva Europe who explores how companies are overcoming challenges to develop, launch, and educate on new rare disease medicines faster.
